ArticleFrontiers in pharmacology2026
Atorvastatin accelerates hematoma absorption and ameliorates cognitive impairment in patients with chronic subdural hematoma complicated by cognitive dysfunction: a retrospective analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic subdural hematoma (CSDH) is a prevalent neurosurgical disorder in the elderly, often accompanied by cognitive impairment that severely compromises prognosis. Atorvastatin promotes hematoma absorption, exerts anti-inflammatory and neuroprotective effects, but its efficacy, cognitive improvement and safety in CSDH patients with cognitive impairment remain unclear. This study aimed to evaluate the impacts of atorvastatin on hematoma resolution, cognitive recovery, surgical conversion risk and safety in this cohort to support clinical conservative management. We conducted a single-center, non-randomized, retrospective study enrolling 67 CSDH patients with cognitive impairment between January 2020 and June 2025, who were assigned to atorvastatin group (routine treatment plus atorvastatin 20 mg nightly) or control group (routine treatment alone). Given the modest sample size and retrospective design, conclusions should be interpreted as exploratory. Primary outcomes included 6-month hematoma absorption rate, absorption grade, corrected MoCA score improvement and cognitive impairment incidence; secondary outcomes included serial hematoma volume, MoCA scores, surgical conversion rate and adverse events. Assessments were performed with the assessors blinded to the treatment group allocation. Baseline characteristics were comparable between the atorvastatin group (n = 33) and control group (n = 34). Atorvastatin significantly reduced hematoma volume and elevated MoCA scores at 1, 3 and 6 months, with higher hematoma absorption rate, lower cognitive impairment rate (6.1% vs. 26.5%) and lower surgical conversion rate (6.1% vs. 26.5%) (all P < 0.05). Hematoma absorption was moderate positively correlated with MoCA improvement (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.